Michael P Citron
Overview
Explore the profile of Michael P Citron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bommakanti G, Citron M, Hepler R, Callahan C, Heidecker G, Najar T, et al.
Proc Natl Acad Sci U S A
. 2010 Jul;
107(31):13701-6.
PMID: 20615991
Influenza HA is the primary target of neutralizing antibodies during infection, and its sequence undergoes genetic drift and shift in response to immune pressure. The receptor binding HA1 subunit of...
12.
Maness N, Wilson N, Reed J, Piaskowski S, Sacha J, Walsh A, et al.
J Immunol
. 2009 Dec;
184(1):67-72.
PMID: 19949108
Rational vaccines designed to engender T cell responses require intimate knowledge of how epitopes are generated and presented. Recently, we vaccinated 8 Mamu-A*02(+) rhesus macaques with every SIV protein except...
13.
Wilson N, Keele B, Reed J, Piaskowski S, Macnair C, Bett A, et al.
J Virol
. 2009 May;
83(13):6508-21.
PMID: 19403685
All human immunodeficiency virus (HIV) vaccine efficacy trials to date have ended in failure. Structural features of the Env glycoprotein and its enormous variability have frustrated efforts to induce broadly...
14.
Fu T, Grimm K, Citron M, Freed D, Fan J, Keller P, et al.
Vaccine
. 2009 Jan;
27(9):1440-7.
PMID: 19146898
Immunization against M2 peptide, also called M2e, from influenza A virus is an innovative vaccine approach for induction of cross-strain protective immunity. Two promising M2 vaccine compositions reported to date...
15.
Fu T, Freed D, Horton M, Fan J, Citron M, Joyce J, et al.
Virology
. 2008 Dec;
385(1):218-26.
PMID: 19070878
M2 protein of influenza A virus has been implicated as a target for vaccines with broad cross-strain coverage. Studies in small animal models have shown that antibody responses induced by...
16.
Liang X, Casimiro D, Schleif W, Wang F, Davies M, Zhang Z, et al.
J Virol
. 2005 Sep;
79(19):12321-31.
PMID: 16160159
Simian-human immunodeficiency virus (SHIV) challenge studies in rhesus macaques were conducted to evaluate the efficacy of adenovirus-based vaccines in the context of different major histocompatibility complex class I genetic backgrounds...
17.
Fan J, Liang X, Horton M, Perry H, Citron M, Heidecker G, et al.
Vaccine
. 2004 Aug;
22(23-24):2993-3003.
PMID: 15297047
A universal influenza virus vaccine that does not require frequent updates and/or annual immunizations will offer significant advantages over current seasonal flu vaccines. The highly conserved influenza virus A M2...
18.
Joyce J, Hurni W, Bogusky M, Garsky V, Liang X, Citron M, et al.
J Biol Chem
. 2002 Sep;
277(48):45811-20.
PMID: 12237296
The synthetic peptide DP178, derived from the carboxyl-terminal heptad repeat region of human immunodeficiency virus type 1 GP41 protein is a potent inhibitor of viral-mediated fusion and contains the sequence...